Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

limited therapeutic choices."

The picoplatin data will be presented in a poster session on Friday, February 27, at 11:45 a.m. Eastern Time (abstract #186/poster #A38) during the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla. Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of solid tumors.

Phase 2 CRPC Trial Design and Results to Date

Patient enrollment in the ongoing Phase 2 trial of picoplatin in patients with metastatic CRPC was completed in December 2007. The trial enrolled 30 patients with metastatic CRPC who had not received prior chemotherapy. The objective of the study is to evaluate the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every three weeks in combination with full doses of docetaxel (75 mg/m squared) with daily prednisone (5 mg) as a first-line treatment. PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint; secondary endpoints include safety, radiologic response, time to progression and overall survival.

The latest trial findings, scheduled for presentation at the ASCO 2009 GU Symposium, demonstrated that:

  • Reductions of PSA levels of at least 50 percent were achieved in 21 of 27 (78 percent) evaluable patients who received picoplatin in combination with docetaxel and prednisone. In contrast, data from published literature report PSA responses of approximately 45 percent in patients who received docetaxel/prednisone.
  • To date, the median time to PSA progression is 8.5 months with picoplatin in combination with docetaxel and prednisone.
  • Radiologic response
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... ANDOVER, Massachusetts , March 4, 2015 /PRNewswire/ ... Unternehmen präsentiert innovative Entwicklungen für Diagnostik und Therapie, ... Gesundheitsversorgung   Royal Philips ... am Europäischen Röntgenkongress 2015 (ECR) bekannt, ... stattfindet. An den Ständen Nr. ...
(Date:3/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... Miami, FL on March 10, 2015 ... , Chief Financial Officer, will provide a corporate overview. ... of Halozyme,s corporate website at www.halozyme.com , and a ... event. To access the live webcast, please log on to ...
(Date:3/3/2015)... LEXINGTON, Ky. (PRWEB) March 03, 2015 ... aligning their schedules for one event: the Alltech REBELation ... USA, from May 17-20. Now in its 31st year, ... people from 70 countries, and the opportunity to join ... week, March 7 at 11:59 p.m. EST, at which ...
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has ... 2015 - 2025" report to their offering. ... an extensive study on the marketed and pipeline gene ... in this field for over a decade but there ... markets; one approved in the EU). There are many ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
... Wis . - The state's mental health statues will ... exchange, according to Madison area health technologists. , ,Patient ... Digital Healthcare Conference 2007 , including one that posed ... data between different health systems would open a ...
... - The search for a new chief information ... University of Wisconsin-Madison has been narrowed to ... ,The finalists are Ronald D. Kraemer, deputy CIO and ... (DoIT); Kathy Pletcher, associate provost for information services and ...
... United States Supreme Court has issued several rulings that ... Microsoft Corp. v. AT&T , the Supreme Court ... that United States patent law governs domestically but does not rule ... , the Supreme Court addressed Section 271(f) of the patent ...
Cached Biology Technology:DHC 2007: Barriers to electronic data exchange include the law 2DHC 2007: Barriers to electronic data exchange include the law 3DHC 2007: Barriers to electronic data exchange include the law 4Supreme Court limits foreign reach of U.S. patents 2Supreme Court limits foreign reach of U.S. patents 3Supreme Court limits foreign reach of U.S. patents 4
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... At 30, Karen Christman, an assistant bioengineering professor at the ... fuel the growing field of tissue engineering. With a new ... of Health (NIH), Christman will be able to do just ... in 2007 to support a small number of new investigators ...
... which human activity is beginning to alter atmospheric composition ... is more pressing than ever that the scientists of ... change in order to anticipate the effects and minimise ... 15?? September at University of Oxford, UK, brought 50 ...
... Armonk, N.Y (September 22, 2008) - IBM ... Technology (KAUST) today announced a joint project ... complex, high-performance computing (HPC) system in the region ... The new system, named Shaheen, will serve the ...
Cached Biology News:Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 3ESA trains next generation of atmospheric scientists 2ESA trains next generation of atmospheric scientists 3KAUST and IBM to build 1 of the fastest and most powerful supercomputers 2KAUST and IBM to build 1 of the fastest and most powerful supercomputers 3
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
... Rabbit polyclonal to MKK6 (phospho S207) ... applications). Antigen: ... around the phosphorylation site of Serine ... Entrez Gene ID: 5608 ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Biology Products: